...
首页> 外文期刊>PLoS Computational Biology >Simultaneous Identification of Multiple Driver Pathways in Cancer
【24h】

Simultaneous Identification of Multiple Driver Pathways in Cancer

机译:同时识别癌症中多个驾驶员途径

获取原文

摘要

Distinguishing the somatic mutations responsible for cancer (driver mutations) from random, passenger mutations is a key challenge in cancer genomics. Driver mutations generally target cellular signaling and regulatory pathways consisting of multiple genes. This heterogeneity complicates the identification of driver mutations by their recurrence across samples, as different combinations of mutations in driver pathways are observed in different samples. We introduce the Multi-Dendrix algorithm for the simultaneous identification of multiple driver pathways de novo in somatic mutation data from a cohort of cancer samples. The algorithm relies on two combinatorial properties of mutations in a driver pathway: high coverage and mutual exclusivity. We derive an integer linear program that finds set of mutations exhibiting these properties. We apply Multi-Dendrix to somatic mutations from glioblastoma, breast cancer, and lung cancer samples. Multi-Dendrix identifies sets of mutations in genes that overlap with known pathways – including Rb, p53, PI(3)K, and cell cycle pathways – and also novel sets of mutually exclusive mutations, including mutations in several transcription factors or other genes involved in transcriptional regulation. These sets are discovered directly from mutation data with no prior knowledge of pathways or gene interactions. We show that Multi-Dendrix outperforms other algorithms for identifying combinations of mutations and is also orders of magnitude faster on genome-scale data. Software available at: http://compbio.cs.brown.edu/software.
机译:将负责癌症(司机突变)的体细胞突变与随机,乘客突变是癌症基因组学中的关键挑战。驱动突变通常靶向由多基因组成的细胞信号传导和调节途径。这种异质性使驾驶员突变的鉴定使其在样品中复发使探测器突变,因为在不同的样品中观察到驾驶员途径中的不同组合。我们介绍了从癌症样本群体中同时识别多个驱动器路径De Novo的多德里克算法。该算法依赖于驾驶员路径中的两个组合性质:高覆盖和互排。我们派生了一个整数线性程序,找到了呈现这些属性的一组突变。我们从胶质母细胞瘤,乳腺癌和肺癌样品中涂抹多德里氏素到躯体突变。多德里克透明鉴定与已知途径重叠的基因中的突变组 - 包括Rb,P53,Pi(3)k和细胞周期途径 - 以及新型的相互排斥突变,包括几种转录因子或其他基因中的突变在转录规则中。这些组直接从突变数据发现,没有现有的途径或基因相互作用。我们表明,多德里克省优于识别突变组合的其他算法,并且在基因组数据中也是更快的数量级。可用的软件:http://compbio.cs.brown.edu/software。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号